mirabegron (Myrbetriq)

From Aaushi
Jump to navigation Jump to search

Introduction

FDA-approved June 2012

Indications

Contraindications

Dosage

  • 25-50 mg P QD

Tabs: 25, 50 mg

Pharmacokinetics

Adverse effects

Drug interactions

Mechanism of action

Notes

  • cost ~ $210/month in 2012

More general terms

Component of

References

  1. FDA News Release: June 28, 2012 FDA approves Myrbetriq for overactive bladder http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310096.htm
  2. Prescriber's Letter 19(10): 2012 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=281026&pb=PRL (subscription needed) http://www.prescribersletter.com CHART: Medications for Overactive Bladder
  3. Tadrous M, Matta R, Greaves S et al Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older - A Population-Based Cohort Study. JAMA Intern Med. Published online July 15, 2019. JAMA Intern Med. Published online July 15, 2019. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2737915

Database